Advances in High Grade Glioma Research

Dear Colleagues,

High-grade gliomas (HGGs), particularly glioblastoma, are among the most aggressive and lethal tumors of the central nervous system, challenging even advanced diagnostic and prognostic strategies.

These tumors grow masked behind a plethora of neurological signs, having systemic effects. Surgery is restricted to the neuroanatomical location, while the blood–brain barrier limits drug treatments. HGGs appear with distinct biological features, establishing a structural relationship within the nervous tissue. The immune distribution is diverse between samples and correlates with tumor cell phenotype in a spatial orientation.

Despite advances in personalized medicine, spatial biology, immunotherapy, and a high-precision ion beam approach, patient prognosis remains unfavorable, requiring urgent studies to understand brain tumor biology, polarization of the microenvironment, and systemic mechanisms.

The combination of diverse treatments and technologies holds promise for improving the prognosis of HGG. The present topic aims to collect ideas, hypotheses, and proofs to leverage the knowledge provided by multitargeted approaches, such as immune checkpoint inhibitors, vaccines, or CAR-T cells, combined with nanomedicine, tumor treating fields (TTFields), artificial intelligence, or radiomics inter-field.

Therefore, journal articles, reviews, letters, and communications related to the aforementioned topics are welcome.

Dr. Assunta Virtuoso
Dr. Agata Grazia D'Amico
Dr. Celeste Caruso Bavisotto
Topic Editors